UnknownPhase 2NCT01178658

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma

Studying Non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Seoul National University Hospital
Principal Investigator: Sung-Soo Yoon
Seoul National University Hospital
Intervention: Busulfan, etoposide, cytarabine, and melphalan(drug)
Enrollment: 42 enrolled
Eligibility: 15-65 years · All sexes
Timeline: 2010

Study locations (5)

Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea

Collaborators

Inje University · Severance Hospital · Asan Medical Center · Ulsan University Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01178658 on ClinicalTrials.gov

Other trials for Non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Non-Hodgkin lymphoma →

← Back to all trials